Overview
Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.
About
CEO
Mr. John Michael Climaco Esq., J.D.
Employees
4
Address
2100 West Loop South
Suite 900
Houston, 77027, TX
United States
Suite 900
Houston, 77027, TX
United States
Phone
800-946-9185
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Germany
MIC code
XFRA